vs
PennyMac Mortgage Investment Trust（PMT）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
PennyMac Mortgage Investment Trust的季度营收约是RIGEL PHARMACEUTICALS INC的1.3倍（$93.6M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 56.0%，领先328.1%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -13.3%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 12.3%）
PennyMac Mortgage Investment Trust是总部位于美国的房地产投资信托，专注于住宅抵押贷款相关资产，主要投资履约及违约抵押贷款、住宅抵押贷款支持证券和信用风险转移工具，业务覆盖美国住房市场的投资管理与抵押贷款服务板块。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
PMT vs RIGL — 直观对比
营收规模更大
PMT
是对方的1.3倍
$69.8M
营收增速更快
RIGL
高出34.5%
-13.3%
净利率更高
RIGL
高出328.1%
56.0%
两年增速更快
RIGL
近两年复合增速
12.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $93.6M | $69.8M |
| 净利润 | $52.4M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 38.6% | 33.2% |
| 净利率 | 56.0% | 384.0% |
| 营收同比 | -13.3% | 21.2% |
| 净利润同比 | 12.5% | 1769.2% |
| 每股收益（稀释后） | $0.49 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PMTRIGL
| Q4 25 | $93.6M | $69.8M | ||
| Q3 25 | $99.2M | $69.5M | ||
| Q2 25 | $70.2M | $101.7M | ||
| Q1 25 | $44.5M | $53.3M | ||
| Q4 24 | $107.9M | $57.6M | ||
| Q3 24 | $80.9M | $55.3M | ||
| Q2 24 | $71.2M | $36.8M | ||
| Q1 24 | $74.2M | $29.5M |
净利润PMTRIGL
| Q4 25 | $52.4M | $268.1M | ||
| Q3 25 | $58.3M | $27.9M | ||
| Q2 25 | $7.5M | $59.6M | ||
| Q1 25 | $9.7M | $11.4M | ||
| Q4 24 | $46.5M | $14.3M | ||
| Q3 24 | $41.4M | $12.4M | ||
| Q2 24 | $25.4M | $-1.0M | ||
| Q1 24 | $47.6M | $-8.2M |
毛利率PMTRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率PMTRIGL
| Q4 25 | 38.6% | 33.2% | ||
| Q3 25 | 47.4% | 40.9% | ||
| Q2 25 | 24.2% | 60.1% | ||
| Q1 25 | -14.2% | 23.9% | ||
| Q4 24 | 51.1% | 28.9% | ||
| Q3 24 | 32.8% | 25.4% | ||
| Q2 24 | 40.2% | 1.2% | ||
| Q1 24 | 43.6% | -23.6% |
净利率PMTRIGL
| Q4 25 | 56.0% | 384.0% | ||
| Q3 25 | 58.7% | 40.2% | ||
| Q2 25 | 10.7% | 58.6% | ||
| Q1 25 | 21.8% | 21.5% | ||
| Q4 24 | 43.1% | 24.9% | ||
| Q3 24 | 51.2% | 22.5% | ||
| Q2 24 | 35.7% | -2.8% | ||
| Q1 24 | 64.2% | -27.9% |
每股收益（稀释后）PMTRIGL
| Q4 25 | $0.49 | $14.11 | ||
| Q3 25 | $0.55 | $1.46 | ||
| Q2 25 | $-0.04 | $3.28 | ||
| Q1 25 | $-0.01 | $0.63 | ||
| Q4 24 | $0.45 | $0.82 | ||
| Q3 24 | $0.36 | $0.70 | ||
| Q2 24 | $0.17 | $-0.06 | ||
| Q1 24 | $0.39 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $190.5M | $155.0M |
| 总债务越低越好 | $1.1B | $52.5M |
| 股东权益账面价值 | $1.9B | $391.5M |
| 总资产 | $21.3B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.58× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资PMTRIGL
| Q4 25 | $190.5M | $155.0M | ||
| Q3 25 | $181.0M | $137.1M | ||
| Q2 25 | $108.6M | $108.4M | ||
| Q1 25 | $204.2M | $77.1M | ||
| Q4 24 | $103.2M | $77.3M | ||
| Q3 24 | $102.8M | $61.1M | ||
| Q2 24 | $336.3M | $49.1M | ||
| Q1 24 | $343.3M | $49.5M |
总债务PMTRIGL
| Q4 25 | $1.1B | $52.5M | ||
| Q3 25 | $299.0M | $60.0M | ||
| Q2 25 | $1.2B | $60.0M | ||
| Q1 25 | $968.4M | $60.0M | ||
| Q4 24 | $1.0B | $60.0M | ||
| Q3 24 | $5.2B | $60.0M | ||
| Q2 24 | $5.4B | $60.0M | ||
| Q1 24 | $5.1B | $60.0M |
股东权益PMTRIGL
| Q4 25 | $1.9B | $391.5M | ||
| Q3 25 | $1.9B | $117.6M | ||
| Q2 25 | $1.9B | $81.9M | ||
| Q1 25 | $1.9B | $18.6M | ||
| Q4 24 | $1.9B | $3.3M | ||
| Q3 24 | $1.9B | $-14.6M | ||
| Q2 24 | $1.9B | $-29.9M | ||
| Q1 24 | $2.0B | $-31.7M |
总资产PMTRIGL
| Q4 25 | $21.3B | $513.6M | ||
| Q3 25 | $18.5B | $242.5M | ||
| Q2 25 | $16.8B | $206.7M | ||
| Q1 25 | $14.9B | $176.0M | ||
| Q4 24 | $14.4B | $164.0M | ||
| Q3 24 | $13.1B | $139.4M | ||
| Q2 24 | $12.1B | $128.4M | ||
| Q1 24 | $12.3B | $126.5M |
负债/权益比PMTRIGL
| Q4 25 | 0.58× | 0.13× | ||
| Q3 25 | 0.16× | 0.51× | ||
| Q2 25 | 0.65× | 0.73× | ||
| Q1 25 | 0.51× | 3.23× | ||
| Q4 24 | 0.52× | 18.25× | ||
| Q3 24 | 2.70× | — | ||
| Q2 24 | 2.76× | — | ||
| Q1 24 | 2.60× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-7.2B | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -137.76× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PMTRIGL
| Q4 25 | $-7.2B | $22.0M | ||
| Q3 25 | $-1.3B | $24.0M | ||
| Q2 25 | $-2.0B | $30.5M | ||
| Q1 25 | $-594.3M | $-893.0K | ||
| Q4 24 | $-2.7B | $14.5M | ||
| Q3 24 | $-983.8M | $21.7M | ||
| Q2 24 | $243.8M | $302.0K | ||
| Q1 24 | $-342.4M | $-5.0M |
现金转化率PMTRIGL
| Q4 25 | -137.76× | 0.08× | ||
| Q3 25 | -22.26× | 0.86× | ||
| Q2 25 | -267.53× | 0.51× | ||
| Q1 25 | -61.39× | -0.08× | ||
| Q4 24 | -58.08× | 1.01× | ||
| Q3 24 | -23.76× | 1.75× | ||
| Q2 24 | 9.59× | — | ||
| Q1 24 | -7.19× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
RIGL
暂无分部数据
